# Program 1 Architecture Review Track Phase B - Conceptual Module Separation and Prohibited Coupling Map

Status: documentation-only, synthetic-only, non-production, non-runtime, pre-implementation architecture review. Not an implementation authorization.

## Purpose

Program 1 Architecture Review Track Phase B defines conceptual module separation and prohibited coupling paths for any possible future Program 1 implementation discussion.

Phase B follows Architecture Review Track Phase A. It is not Phase Z+1 and is not a return to the Phase V-Z governance/prototype sequence.

Program 1 remains in pre-implementation hold.

## Track continuity

Phase A established a synthetic-only pre-implementation architecture boundary. Phase B uses that boundary to describe which conceptual layers may be discussed and which couplings remain prohibited because they could accidentally create runtime clinical behavior, real-data handling, write-capable workflows, patient communication, appointment mutation, audit/auth runtime behavior, or approval/override capability.

## Scope

- Conceptual module separation.
- Synthetic documentation layer boundary.
- Future read-only layer boundary, as concept only.
- Future clinical review layer boundary, as concept only.
- Prohibited write-capable, patient communication, appointment mutation, workflow enforcement, and approval/clearance/override boundaries.
- Deferred security, audit, and authorization layer discussion.
- Prohibited coupling map.

## Non-scope

Phase B does not add runtime code, tests, helpers, scripts, imports, services, migrations, endpoints, UI flows, schedulers, task runners, integrations, runtime auth/authz/RBAC, runtime audit logging, patient messaging, appointment mutation, workflow enforcement, Task engine, Outcome Evidence, clinical write workflows, approval/clearance/override runtime capability, production-readiness claim, or go-live authorization.

## Safety boundaries

Phase B is documentation-only, synthetic-only, non-production, non-runtime, pre-implementation, not an implementation authorization, not a production-readiness review, and not a clinical deployment review.

Phase B does not approve production use, real patient data, PHI/PII processing, live clinical deployment, clinical validation, operational clearance, go-live, runtime implementation, or approval/clearance/override behavior.

## Phase A input summary

Phase A established:

- Synthetic-only architecture boundary.
- Permitted future discussion areas.
- Prohibited runtime paths.
- Data classification preview.
- Read-only vs write-capable conceptual distinction.
- Human-in-the-loop responsibility preview.
- Future approval dependency map.

## Conceptual module separation model

| Conceptual module | Allowed current status | Prohibited current status | Runtime status | Data boundary | Future authorization dependency |
| --- | --- | --- | --- | --- | --- |
| Synthetic documentation layer | Allowed as the only current layer | Runtime or real-data artifact | None | Synthetic and abstract only | Required before any move beyond documentation |
| Architecture review layer | Allowed as text-only review | Executable design or implementation | None | Synthetic and abstract only | Required before technical design execution |
| Future read-only reference layer | Conceptual only | Runtime read access | Not implemented | No real data or PHI/PII | Explicit future authorization |
| Future clinical review layer | Conceptual only | Clinical deployment or autonomous action | Not implemented | No patient data | Clinical safety and accountability review |
| Prohibited write-capable layer | Not allowed | Any mutation/writeback path | Prohibited | Not applicable | Separate future authorization required before reconsideration |
| Prohibited patient communication layer | Not allowed | Patient-facing or staff-mediated communication | Prohibited | Not applicable | Separate future authorization required before reconsideration |
| Prohibited appointment mutation layer | Not allowed | Scheduling or status mutation | Prohibited | Not applicable | Separate future authorization required before reconsideration |
| Prohibited workflow enforcement layer | Not allowed | Runtime enforcement or clinical workflow execution | Prohibited | Not applicable | Separate future authorization required before reconsideration |
| Prohibited approval/clearance/override layer | Not allowed | Approval, clearance, or override execution | Prohibited | Not applicable | Separate future authorization required before reconsideration |
| Deferred security/audit/authorization layer | Conceptual only | Runtime RBAC, audit capture, policy enforcement | Not implemented | No production or PHI/PII data | Security architecture review and explicit future authorization |

## Synthetic documentation layer boundary

The synthetic documentation layer is the only currently allowed layer. It may contain markdown documentation, conceptual diagrams in text, synthetic examples, abstract placeholders, non-patient scenarios, and non-runtime architectural descriptions.

It must not contain runtime code, real patient data, PHI/PII, live clinic data, clinical write behavior, patient messaging, appointment mutation, approval logic, or override logic.

## Future read-only layer boundary

Read-only is a future concept only. Phase B does not authorize read-only runtime access.

Any future read-only concept would require no mutation, no writeback, no patient communication, no appointment mutation, no clinical instruction delivery, no workflow enforcement, and no autonomous action.

## Future clinical review layer boundary

The future clinical review layer is a human-in-the-loop concept only. It is not implemented and not authorized.

Any future clinical review layer would require licensed clinician accountability, explicit human review, a documented responsibility model, no autonomous diagnosis, no autonomous treatment, no automatic patient instruction, and no automatic workflow enforcement.

## Prohibited write-capable layer boundary

Write-capable behavior is prohibited in Phase B. Prohibited behavior includes patient profile mutation, appointment status mutation, clinical note writing, diagnosis writing, treatment recommendation execution, medication or instruction generation for patient delivery, task creation or assignment, Outcome Evidence creation, workflow enforcement, and approval/clearance/override execution.

## Prohibited patient communication boundary

Phase B does not permit patient messaging, patient instructions, patient reminders, patient portal output, automated summaries to patients, direct patient communication, or indirect patient communication through staff workflow.

## Prohibited appointment mutation boundary

Phase B does not permit creating appointments, cancelling appointments, rescheduling appointments, changing appointment status, triage-driven scheduling mutation, automated queue movement, or operational scheduling enforcement.

## Deferred security, audit, and authorization layer

Auth/authz/RBAC, audit logging, and security architecture remain deferred conceptual areas. Phase B does not implement RBAC, runtime authorization, audit logging capture, audit event storage, access enforcement, policy enforcement, approval gates, or override gates.

## Prohibited coupling map

| Source concept | Prohibited target | Why prohibited | Current decision | Required future authorization before reconsideration |
| --- | --- | --- | --- | --- |
| Synthetic documentation layer | Real patient data | Would break synthetic-only boundary | Prohibited | Real-data governance, privacy/legal, security, and explicit hold-exit authorization |
| Architecture review layer | Runtime code | Would turn review into implementation | Prohibited | Explicit implementation authorization |
| Future read-only layer | Write-capable operations | Would create mutation risk | Prohibited | Clinical safety, governance, validation, and implementation authorization |
| Clinical review layer | Autonomous diagnosis | Would create autonomous clinical behavior | Prohibited | Clinical safety and accountability authorization |
| Clinical review layer | Autonomous treatment | Would create autonomous clinical behavior | Prohibited | Clinical safety and accountability authorization |
| Read-only layer | Patient messaging | Would create patient communication path | Prohibited | Patient communication governance and explicit implementation authorization |
| Read-only layer | Appointment mutation | Would create scheduling mutation path | Prohibited | Scheduling governance and explicit implementation authorization |
| Audit concept | Runtime audit capture | Would create runtime audit behavior | Prohibited | Security/audit architecture and implementation authorization |
| Authorization concept | Runtime RBAC enforcement | Would create runtime access enforcement | Prohibited | Security architecture, validation plan, and implementation authorization |
| Blocker map | Approval/override capability | Would imply clearance or override behavior | Prohibited | Separate governance authorization; no automatic approval |
| Documentation state | Production-readiness claim | Would overstate maturity | Prohibited | Production governance review and formal future authorization |
| Roadmap entry | Go-live authorization | Would confuse planning with deployment | Prohibited | Separate go-live decision in a future authorized phase |

## Explicit non-approval statement

Phase B does not approve implementation, production use, real-data use, PHI/PII processing, clinical deployment, go-live, runtime authorization, runtime audit logging, patient messaging, appointment mutation, workflow enforcement, clinical write workflows, or approval/clearance/override capability.

## Next-step decision

Recommended next phase: `Program 1 Architecture Review Track Phase C - Conceptual Data Flow and Synthetic Boundary Trace`.

If opened, Phase C should remain documentation-only and synthetic-only. Phase C must not introduce runtime implementation.

## Closure statement

Architecture Review Track Phase B closes with Program 1 still in pre-implementation hold. All runtime, production, real-data, PHI/PII, clinical workflow, patient communication, appointment mutation, workflow enforcement, approval/clearance/override, and go-live boundaries remain active.
